Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VCYT | US
1.18
3.56%
Healthcare
Biotechnology
30/06/2024
24/04/2026
34.33
33.21
34.51
32.83
Veracyte Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome Inc. and changed its name to Veracyte Inc. in March 2008. Veracyte Inc. was incorporated in 2006 and is headquartered in South San Francisco California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
43.7%1 month
50.3%3 months
47.7%6 months
60.8%-
31.75
2.34
0.02
0.02
-26.62
6.08
-
32.18M
2.64B
2.64B
-
4.72
-
26.70
-4.88
3.91
4.74
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
4.63
Range1M
5.72
Range3M
14.21
Rel. volume
0.69
Price X volume
16.96M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Denali Therapeutics Inc | DNLI | Biotechnology | 19.87 | 2.84B | 2.16% | n/a | 3.51% |
| TNGX | TNGX | Biotechnology | 25.77 | 2.76B | -0.39% | n/a | 15.28% |
| STROUDS INC | STRO | Biotechnology | 33.33 | 2.73B | -4.31% | n/a | 125.14% |
| ARCUTIS BIOTHERAPEUTICS INC. | ARQT | Biotechnology | 23.26 | 2.72B | 1.75% | n/a | 111.34% |
| NewAmsterdam Pharma Company N.V. Ordinary Shares | NAMS | Biotechnology | 29.72 | 2.68B | -5.53% | n/a | 0.15% |
| ADMA Biologics Inc | ADMA | Biotechnology | 11.26 | 2.62B | 1.62% | 112.71 | 75.10% |
| Structure Therapeutics Inc. American Depositary Shares | GPCR | Biotechnology | 45.49 | 2.60B | -3.25% | n/a | 0.51% |
| IDEAYA Biosciences Inc | IDYA | Biotechnology | 30.73 | 2.60B | 0.10% | n/a | 0.20% |
| Relay Therapeutics Inc. | RLAY | Biotechnology | 15.13 | 2.46B | 0.27% | n/a | 7.50% |
| Kodiak Sciences Inc | KOD | Biotechnology | 44.84 | 2.36B | -0.82% | n/a | 81.94% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Pitney Bowes Inc | PBI | Building Products & Equipment | 15.58 | 2.80B | 1.37% | n/a | -571.93% |
| HNI Corporation | HNI | Building Products & Equipment | 37.7 | 1.78B | 1.32% | 22.12 | 76.47% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.6 | 1.46B | 3.03% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 39.11 | 1.23B | -1.21% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 32.87 | 951.75M | 0.70% | 22.53 | 56.33% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.44 | 790.55M | 1.30% | 11.62 | 116.21% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 17.7 | 737.79M | 2.31% | 42.05 | 64.69% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.01 | 694.62M | -0.17% | 65.18 | 77.00% |
| Ennis Inc | EBF | Building Products & Equipment | 20.33 | 528.66M | -1.26% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 26.1 | 521.76M | -0.91% | n/a | 1.50% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -26.62 | 0.53 | Cheaper |
| Ent. to Revenue | 6.08 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.34 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 47.67 | 72.80 | Lower Risk |
| Debt to Equity | 0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 2.64B | 3.66B | Emerging |